Recon: FDA panel reviews Pfizer, GSK RSV vaccines; Merck scraps Keytruda prostate cancer trial after disappointing Phase III results
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy